SCHEMBL3200150

SCHEMBL3200150

CNC(=O)c1ccc(N(Cc2cncs2)c2ccc(OC(F)F)c(OC(F)F)c2)cc1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 9/20 0.35
PDE4D Q08499 7/20 0.35
PDE4A P27815 5/20 0.35
PDE4C Q08493 5/20 0.35
LMNA P02545 3/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ABCB11 O95342 1/20 0.34
FAAH O00519 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
RAB9A P51151 1/20 0.33
CTSL P07711 1/20 0.33
MAPK1 P28482 1/20 0.33
PDK1 Q15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3203145 0.89 PDE4D (0.37) PDE4BPDE4DPDE4APDE4CABCB11
SCHEMBL3122844 0.88 PDE4A (0.40) PDE4BPDE4DPDE4APDE4C
SCHEMBL3209442 0.87 PDE4A (0.43) PDE4BPDE4DPDE4APDE4CHTT
SCHEMBL3191879 0.87 PARP15 (0.46) PDE4BPDE4DPDE4APDE4CKDM4E
SCHEMBL3193291 0.86 PCSK9 (0.39) PDE4BPDE4DPDE4APDE4CLMNA
SCHEMBL3125745 0.86 RXRA (0.48) PDE4BPDE4DPDE4APDE4C
SCHEMBL3126060 0.85 HDAC6 (0.37) PDE4BPDE4DPDE4APDE4CRAB9A
SCHEMBL3125356 0.85 RXRA (0.39) PDE4BPDE4DPDE4APDE4CKDM4E
SCHEMBL3131039 0.85 RXRA (0.39) PDE4BPDE4DPDE4APDE4CLMNA
SCHEMBL3209226 0.83 SMN1; SMN2 (0.36) LMNAMAPTKDM4EHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B PDE4B 2/4885PDE4D 9/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.